Want to cut your energy bills? Here’s how five experts are doing it 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
CAMBRIDGE, Mass., March 10, 2016 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that it will host its fourth quarter and full year 2015 investor update call before the open of the U.S. financial markets on Thursday, March 17, 2016. Voyager management will host a conference call and live audio webcast at 8:30 a.m. ET the same day.
The live call may be accessed by dialing (877) 489-6517 for domestic callers or +1 (929) 387-3945 for international callers, and referencing conference ID number 51816666. A live audio webcast of the conference call will be available online from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease and spinal muscular atrophy (SMA). Voyager has broad strategic collaborations with Genzyme Corporation, a Sanofi company, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
Contact: Investor Relations: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 [email protected] Media: Katie Engleman Pure Communications, Inc. 910-509-3977 [email protected]
